Skip to content
Friday, October 23, 2026 · Today’s edition, 6:30 a.m. ETFri, Oct 23 · 6:30 a.m. editionSign inMy Desk 0EditionsSign in
BIBProSharesINDEX

ProShares Ultra Nasdaq Biotechnology

$112.85-1.62% vs prior close
6612652-WK

Price through Oct 22, 2026 · Flows through Oct 21, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Oct 22, 2026. Holdings snapshot retrieved Oct 22, 2026.

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

BIB price

Source: Market tape, daily closes; price return, distributions not reinvested
Table
DateBIB close
Sep 22, 2026$117.16
Sep 23, 2026$112.04
Sep 24, 2026$114.26
Sep 25, 2026$114.42
Sep 28, 2026$115.63
Sep 29, 2026$115.88
Sep 30, 2026$115.45
Oct 1, 2026$110.47
Oct 2, 2026$109.80
Oct 5, 2026$112.06
Oct 6, 2026$106.90
Oct 7, 2026$107.46
Oct 8, 2026$105.02
Oct 9, 2026$110.98
Oct 12, 2026$108.79
Oct 13, 2026$103.59
Oct 14, 2026$106.82
Oct 15, 2026$111.11
Oct 16, 2026$105.10
Oct 19, 2026$107.09
Oct 20, 2026$113.95
Oct 21, 2026$114.71
Oct 22, 2026$112.85

Daily net flows, 1M

Net inflow over the range: +$0M

$0Sep 21Sep 23Sep 25Sep 29Oct 1Oct 5Oct 7Oct 9Oct 13Oct 15Oct 19$0Oct 21$0Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15$0Oct 21$0Sep 21Sep 29Oct 7Oct 15$0Oct 21
Source: Daily creation and redemption records
Show as table
LabelValue ($)
Sep 21$0
Sep 22$0
Sep 23$0
Sep 24$0
Sep 25$0
Sep 28$0
Sep 29$0
Sep 30$0
Oct 1$0
Oct 2$0
Oct 5$0
Oct 6$0
Oct 7$0
Oct 8$0
Oct 9$0
Oct 12$0
Oct 13$0
Oct 14$0
Oct 15$0
Oct 16$0
Oct 19$0
Oct 20$0
Oct 21$0
The desk’s read

Flows are quiet — the past month netted out near zero, while the price has returned +41.4% so far this year. At 0.95% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.

COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH

$96Massets under management
0.95%expense ratio · $95 per $10,000 a year
—net flow, trailing month
8Kavg daily volume, 30 days
229holdings · US-domiciled
2010listed April 9, 2010 · beta 1.54

Sector weights

  • Healthcare100%
  • Other72.51%
  • Health Technology69.19%
  • Cash29.28%
  • Commercial Services1.36%
  • Health Services0.16%
Source: Portfolio composition, latest disclosure
Show as table
ItemValue (%)
Healthcare100%
Other72.51%
Health Technology69.19%
Cash29.28%
Commercial Services1.36%
Health Services0.16%

Country weights

  • United States88.94%
  • Other69.75%
  • United Kingdom5.32%
  • France1.49%
  • Germany0.9%
  • China0.89%
  • Denmark0.86%
  • Switzerland0.45%
Source: Portfolio composition, latest disclosure
Show as table
ItemValue (%)
United States88.94%
Other69.75%
United Kingdom5.32%
France1.49%
Germany0.9%
China0.89%
Denmark0.86%
Switzerland0.45%
Performance
1 week+7.4%
1 month-3.7%
3 months+15.9%
6 months+27.5%
YTD+41.4%
1 year+70.7%
3 years—

PRICE RETURN, DISTRIBUTIONS NOT REINVESTED

Net flows
1 week—
1 month—
3 months+$660K
YTD−$17M
1 year−$11M

CREATION/REDEMPTION DOLLARS, DAILY RECORDS

Monthly net flows

  • Inflow / above zero
  • Outflow / below zero
+$6MNov+$10KDec−$40KJan−$890KFeb−$4MMar−$5.1MApr−$4.8MMay−$3.6MJun−$1.9MJul+$7MAug−$3.3MSep$0Oct+$6MNov+$10KDec−$40KJan−$890KFeb−$4MMar−$5.1MApr−$4.8MMay−$3.6MJun−$1.9MJul+$7MAug−$3.3MSep$0OctNovJanMarMayJul+$7M$0Oct
Source: Daily creation/redemption records, trailing twelve months
Show as table
LabelValue ($)
Nov$6M
Dec$10K
Jan−$40K
Feb−$890K
Mar−$4M
Apr−$5.1M
May−$4.8M
Jun−$3.6M
Jul−$1.9M
Aug$7M
Sep−$3.3M
Oct$0
The risk read
53%realized volatility, 30 days (annualized)
45%realized volatility, 1 year
-17.9%deepest fall from a peak, 1 year
-10.6%latest close versus that peak

VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK

Options tape
83calls · latest snapshot
26puts · latest snapshot
0.31put/call ratio
8Kshares traded
The case against BIB

Due diligence cuts both ways. These funds sit on the same shelf and beat BIB on at least one dimension that matters — the fee, the asset base, or where the money is going.

FundFeeAssetsFlow, 1MThe case
IVV iShares Core S&P 500 ETF0.03%$890.4B+$33.3B-92bp on fee · 9248× the assets · +$33.3B in over the monthHead-to-head
SPDW SPDR Portfolio Developed World ex-US ETF0.03%$41.2B+$609M-92bp on fee · 428× the assets · +$609M in over the monthHead-to-head
BBUS JPMorgan BetaBuilders U.S. Equity ETF0.02%$9.6B+$187M-93bp on fee · 100× the assets · +$187M in over the monthHead-to-head
SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF0.03%$18.4B+$199M-92bp on fee · 191× the assets · +$199M in over the monthHead-to-head
SPYG State Street SPDR Portfolio S&P 500 Growth ETF0.04%$57.9B+$717M-91bp on fee · 601× the assets · +$717M in over the monthHead-to-head
Sign in to save this to The RecordA timestamped copy for the file — documentation, not advice.
ETF Dailyfrom Private Wealth Daily

ETF launches, fund research, and market coverage in your inbox every weekday. Free.

Free. Weekday mornings. Unsubscribe from any edition in one click.